PRA is one of the world's leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA's global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 18,100 employees worldwide. Since 2000, PRA has participated in approximately 4,200 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 100 drugs.
Company profile
Ticker
PRAH
Exchange
Website
CEO
Colin Shannon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • Charles River Laboratories International • Syneos Health • Icon • Medpace • Incyte • Zymergen • OmniAb • SomaLogic ...
SEC CIK
Corporate docs
PRAH stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
13 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 21
POSASR
Automatic shelf registration (post-effective amendment)
1 Jul 21
25-NSE
Exchange delisting
1 Jul 21
8-K
Entry into a Material Definitive Agreement
1 Jul 21
8-K
Completion of Acquisition or Disposition of Assets
1 Jul 21
8-K
Departure of Directors or Certain Officers
25 Jun 21
Transcripts
PRAH
Earnings call transcript
2020 Q3
7 Nov 20
PRAH
Earnings call transcript
2020 Q2
7 Aug 20
PRAH
Earnings call transcript
2020 Q1
1 May 20
PRAH
Earnings call transcript
2019 Q4
21 Feb 20
PRAH
Earnings call transcript
2019 Q3
31 Oct 19
PRAH
Earnings call transcript
2019 Q2
3 Aug 19
PRAH
Earnings call transcript
2019 Q1
4 May 19
PRAH
Earnings call transcript
2018 Q4
28 Feb 19
PRAH
Earnings call transcript
2018 Q3
1 Nov 18
PRAH
Earnings call transcript
2018 Q2
4 Aug 18
Latest ownership filings
SC 13G/A
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
2 Feb 22
SC 13G
INTEGRATED CORE STRATEGIES (US) LLC
12 Jul 21
SC 13G/A
VANGUARD GROUP INC
12 Jul 21
4
Christopher L Gaenzle
1 Jul 21
4
COLIN SHANNON
1 Jul 21
4
Michael J. Bonello
1 Jul 21
4
Matthew P. Young
1 Jul 21
4
Glen D. Stettin
1 Jul 21
4
JAMES C MOMTAZEE
1 Jul 21
4
Linda Grais
1 Jul 21
Financial summary
Quarter (USD) | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|